The U.S. Food and Drug Administration has approved Myrbetriq (mirabegron) tablets for the treatment of overactive bladders (OAB), the U.S. subsidiary of Japanese drug maker Astellas Pharma Inc. said on June 28.
“The approval of Myrbetriq represents an important milestone in OAB treatment and in our ongoing commitment to advancing urological health,” Steven Ryder, president of Astellas Pharma Global Development, said in a statement.
Myrbetriq is a once daily oral beta-3 adrenergic agonist discovered and developed by Astellas. It has been studied extensively in more than 10,000 individuals over 10 years.
- « Prev
- Next »